ReviewCancers2021
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026Guideline
- Trial
- Next-Generation Sequencing for Minimal Residual Disease Detection in Pediatric Acute Lymphoblastic Leukemia: Technological Advances, Clinical Translations and Current Challenges.Current issues in molecular biology · 2026Review
- Outcomes of Childhood Acute Lymphoblastic Leukemia Treated with Modified BFM-2009 Protocol Using Measurable Residual Disease-Based Risk-Stratification: A Single-Center Study.Indian pediatrics · 2026Article
- Liver involvement in pediatric acute leukemia: subtype differences and complex hepatic injury as a novel marker for AML risk stratification.Frontiers in oncology · 2026Article
- Glycosylation converts CD24 from a developmental marker into a glyco-immune checkpoint in B-cell acute lymphoblastic leukemia.Frontiers in immunology · 2026Review
- Post-Transplant Relapse in Acute Leukemia: Comparative Value of MRD and Chimerism.Mediterranean journal of hematology and infectious diseases · 2026Article
- Cytogenetic landscape aberrations in paediatric acute lymphoblastic leukaemia - a polish paediatric population treated according to ALL-IC BFM 2009 protocol.Scientific reports · 2025Article
- Precision Medicine in Hematologic Malignancies: Evolving Concepts and Clinical Applications.Biomedicines · 2025Review
- Review
- Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions.Discover oncology · 2025Review
- A long-term survivor of congenital KMT2A-R B-lymphoblastic leukemia with persistently positive bone marrow MRD and multiple CNS relapses.BMC pediatrics · 2025Article
- Clinical characteristics and prognostic analysis of different fusion gene abnormalities in childhood acute lymphoblastic leukaemia.Frontiers in oncology · 2025Article
- Hyper-CVAD in Adults With Acute Lymphoblastic Leukemia in Ecuador: A Multicenter Retrospective Study.Advances in hematology · 2025Article
- Minimal residual disease monitoring by Ig/TCR gene rearrangements predicts post-transplant relapse and survival in adult patients with acute lymphoblastic leukemia.Annals of hematology · 2024Article
- Children With Acute Lymphoblastic Leukemia in Romania: Results From a Decade-Long Single-Center Study.Cureus · 2024Article
- Prevalence and Treatment Outcomes of Childhood Acute Lymphoblastic Leukemia in Kosovo.Cancers · 2024Article
- Genetic alterations in lymphoblastic leukaemiaMedizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2024Article
- Gene expression prognostic of early relapse risk in low-risk B-cell acute lymphoblastic leukaemia in children.EJHaem · 2024Article
- miRNAs as predictive biomarkers of response to treatment in pediatric patients with acute lymphoblastic leukemia.Oncology letters · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer and advances in its clinical and laboratory biology have grown exponentially over the last few decades. Treatment outcome has improved steadily with over 90% of patients surviving 5 years from initial diagnosis. This success can be attributed in part to the development of a risk stratification approach to identify those subsets of patients with an outstanding outcome that might qualify for a reduction in therapy associated with fewer short and long term side effects. Likewise, recognition of patients with an inferior prognosis allows for augmentation of therapy, which has been shown to improve outcome. Among the clinical and biological variables known to impact prognosis, the kinetics of the reduction in tumor burden during initial therapy has emerged as the most important prognostic variable. Specifically, various methods have been used to detect minimal residual disease (MRD) with flow cytometric and molecular detection of antigen receptor gene rearrangements being the most common. However, many questions remain as to the optimal timing of these assays, their sensitivity, integration with other variables and role in treatment allocation of various ALL subgroups. Importantly, the emergence of next generation sequencing assays is likely to broaden the use of these assays to track disease evolution. This review will discuss the biological basis for utilizing MRD in risk assessment, the technical approaches and limitations of MRD detection and its emerging applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.